January 27, 2015 11:42 PM ET

Healthcare Equipment and Supplies

Company Overview of Entellus Medical, Inc.

Company Overview

Entellus Medical, Inc., a medical technology company, designs, develops, and commercializes products for the minimally invasive treatment of patients in the physician office setting or operating room suffering from chronic sinusitis. It offers XprESS Multi-Sinus Dilation family of products consisting of XprESS device and XprESS LoProfile device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation; and FinESS sinus dilation system, a solution for treatment of the maxillary sinus drainage pathway. The company also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides high intensity red transillumin...

3600 Holly Lane North

Suite 40

Plymouth, MN 55447

United States

Founded in 2006

166 Employees

Phone:

763-463-1595

Key Executives for Entellus Medical, Inc.

Chairman of the Board and Chief Executive Officer
Age: 57
President and Chief Operating Officer
Age: 52
Co-Founder
Co-Founder and Member of Scientific Advisory Board
Chief Financial Officer
Age: 51
Compensation as of Fiscal Year 2014.

Entellus Medical, Inc. Key Developments

Entellus Medical Mulls Acquisitions

Entellus Medical, Inc. is looking for acquisitions. Entellus Medical, Inc. has filed an initial public offering in the amount of $69 million and intends to use a portion of the net proceeds to co-develop, acquire or invest in products, technologies or businesses that are complementary to their business.

Oxford Finance Closes $25 Million Senior Credit Facility with Entellus Medical

Oxford Finance LLC announced that it entered into a term loan agreement with Entellus Medical, Inc. that expanded the original $17 million loan facility to $25 million. Entellus is using proceeds of the loan to support business operations and the ongoing marketing efforts for its minimally invasive treatments for chronic sinusitis.

Entellus Medical and CogENT Therapeutics Announce Distribution Agreement

Entellus Medical and CogENT Therapeutics announced they have reached an exclusive distribution agreement. Entellus will distribute CogENT's XeroGel(R) nasal/epistaxis pack to ENT physicians. The agreement makes Entellus Medical the sole distributor of XeroGel in the United States. XeroGel nasal/epistaxis pack is a dissolvable co-polymer of chitosan and polyethylene glycol. Upon placement, the pack absorbs fluids in the surgical field and conforms to the treatment site in order to minimize post-surgical bleeding, prevent adhesions between mucosal surfaces, and aid in the natural healing process. In addition, XeroGel can be used for the treatment of epistaxis.

Similar Private Companies By Industry

Company Name Region
Memtec Corporation United States
ClorDiSys Solutions, Inc. United States
Suspension Orthopaedic Solutions, LLC United States
iTi Health, Inc. United States
Senior Scientific LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Entellus Medical, Inc., please visit www.entellusmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.